Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans
August 30 2016 - 12:14PM
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage
pharmaceutical company, today announced it will provide an overview
of top-line results from its Phase 2b STORM study and the planned
development path for selinexor (KPT-330) in multiple myeloma (MM)
on Tuesday, September 6, 2016, followed by a conference call on
Tuesday, September 6, 2016 at 8:30 a.m., Eastern time. To
access the conference call, please dial (855) 437-4406 (US) or
(484) 756-4292 (international) at least five minutes prior
to the start time and refer to conference ID: 74213103.
Accompanying slides will be available under "Events
& Presentations" in the "Investor" section of Karyopharm's
website, http://www.karyopharm.com, where an audio recording
of the call will be available approximately two hours after the
event.
Karyopharm today confirmed that, as had been reported on
clinicaltrials.gov, it intends to expand its Phase 2b STORM study
evaluating the activity of selinexor in multiple myeloma (MM) to
include approximately 120 additional patients with penta-refractory
MM. Patients with penta-refractory myeloma have previously
received two proteasome inhibitors (PIs) (bortezomib (Velcade®) and
carfilzomib (Kyprolis®)) and two immunomodulatory agents (IMiDs)
(lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)), and their
disease is refractory to at least one PI, at least one IMiD and an
anti-CD38 monoclonal antibody, such as daratumumab (Darzalex™) or
isatuximab, and has progressed following their most recent
therapy. Selinexor, the Company’s lead, novel, oral Selective
Inhibitor of Nuclear Export / SINE™ compound, is being developed
for the treatment of a variety of malignancies, including MM.
About Karyopharm Therapeutics Karyopharm
Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical
company focused on the discovery and development of novel
first-in-class drugs directed against nuclear transport and related
targets for the treatment of cancer and other major diseases.
Karyopharm's SINE™ compounds function by binding with and
inhibiting the nuclear export protein XPO1 (or CRM1). In addition
to single-agent and combination activity against a variety of human
cancers, SINE™ compounds have also shown biological activity in
models of neurodegeneration, inflammation, autoimmune disease,
certain viruses and wound-healing. Karyopharm, which was founded by
Dr. Sharon Shacham, currently has several investigational programs
in clinical or preclinical development. For more information,
please visit www.karyopharm.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding the therapeutic
potential of and potential clinical development plans for
Karyopharm's drug candidates, including the reporting of data from
such trials. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company's current
expectations. For example, there can be no guarantee that selinexor
(KPT-330) will successfully complete necessary preclinical and
clinical development phases or that development of selinexor will
continue. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
factors, including the following: Karyopharm's results of clinical
trials and preclinical studies, including subsequent analysis of
existing data and new data received from ongoing and future
studies; the content and timing of decisions made by the U.S. Food
and Drug Administration and other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies, including with respect to the need for
additional clinical studies; Karyopharm's ability to obtain and
maintain requisite regulatory approvals and to enroll patients in
its clinical trials; unplanned cash requirements and expenditures;
development of drug candidates by Karyopharm's competitors for
diseases in which Karyopharm is currently developing its drug
candidates; and Karyopharm's ability to obtain, maintain and
enforce patent and other intellectual property protection for any
drug candidates it is developing. These and other risks are
described under the caption "Risk Factors" in Karyopharm's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2016,
which was filed with the Securities and Exchange Commission (SEC)
on August 4, 2016, and in other filings that Karyopharm may make
with the SEC in the future. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Karyopharm expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Velcade® is a registered trademark of Takeda Pharmaceutical
Company LimitedRevlimid® and Pomalyst® are registered trademarks of
Celgene CorporationKyprolis® is a registered trademark of Onyx
Pharmaceuticals, Inc.Darzalex™ is a trademark of Janssen Biotech,
Inc.
Contact:
Justin Renz
(617) 658-0574
jrenz@karyopharm.com
Gina Nugent
(617) 460-3579
nugentcomm@aol.com
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024